Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 21Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Burkitt Lymphoma 6Leukemia, Biphenotypic, Acute 5Recurrence 3Smoldering Multiple Myeloma 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, T-Cell 2Lymphoma, Large B-Cell, Diffuse 2Leukemia 2Immunoglobulin Light-chain Amyloidosis 2Hodgkin Disease 2Blastic Plasmacytoid Dendritic Cell Neoplasm 2Renal Insufficiency 1Proteostasis Deficiencies 1Neoplasms, Plasma Cell 1Neoplasms 1Meningioma 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Lymphoma 1Lymphodepleting Chemotherapy 1Lung Neoplasms 1Leukemia, Myelomonocytic, Chronic 1Hematologic Neoplasms 1Down Syndrome 1Cytokine Release Syndrome 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1

Interventions

siltuximab 2tocilizumab 1talquetamab 1obinutuzumab 1glofitamab 1Oxaliplatin 1Gemcitabine 1Dexamethasone 1Calcium Dobesilate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Cytokine Release Syndrome × Calcium Dobesilate × Clear all
NCT05972135 2026-04-22

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

SCRI Development Innovations, LLC

Phase 2 Recruiting
100 enrolled
Plasma cell

Cytokine Release Syndrome, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡